Dr Lal PathLabs

February 8, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended December 31, 2018

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended December 31, 2018.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head

Encl: As above

For Immediate Release **February 8, 2019**

Dr. Lal PathLabs Limited records revenue growth of 11.3% to Rs 2,925 mn in Q3 FY2018-19

New Delhi, India, Feb 8, 2019 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2018

Consolidated Performance Highlights: Q3FY2018-19 vs Q3FY2017-18
Revenue growth: 11.3% at Rs 2,925 mn,
Normalised EBITDA at Rs 706 mn, PBT at Rs 679 mn
Normalised EBITDA margins at 24.1% vs 23.1% last year and
PAT Rs 461 mn with margin at 15.8%

- Operating Revenue increased by 11.3% in Q3 to Rs. 2,925 million vs Rs 2,627 million in the previous year same quarter. Underlying volume growth is 12.1% during the quarter.
- Normalised EBITDA in Q3FY19 grew 16.3% to Rs.706 million from Rs 607 million in the same quarter last year, after adjustment for stock based compensation costs and CSR expense.
- Normalised EBITDA Margin at 24.1% for Q3 FY19 vs 23.1% in Q3 FY18.
- PBT is at Rs 679 mn in Q3 vs Rs 555 mn in Q3 last year.
- Profit after Tax in Q3FY19 at Rs. 461 million as compared to Rs 363 million in Q3 last year.

Financial Overview (Consolidated) in Rs mn

Particulars	Q3 FY19	Q3 FY18	*Growth %*	YTD Dec' 18	YTD Dec' 17	*Growth %*
Total Revenue	**2,925**	**2,627**	***11.3%***	**9,023**	**7,901**	***14.2%***
Total Expenditure	2,269	2,061		6,749	5,901	
EBITDA	**656**	**566**	***15.9%***	**2,274**	**2,000**	***13.7%***
Adj for Stock based comp. & CSR cost	50	41		130	95	
Normalised EBITDA	**706**	**607**	***16.3%***	**2,404**	**2,095**	***14.7%***
Normalised Margins	*24.1%*	*23.1%*		*26.6%*	*26.5%*	
Other income incl. interest	122	71		325	223	
PBT	**679**	**555**	***22.3%***	**2,314**	**1,993**	***16.1%***
Margins	*23.2%*	*21.1%*		*25.6%*	*25.2%*	
PAT	**461**	**363**	***27.0%***	**1,531**	**1,315**	***16.4%***
Margins	*15.8%*	*13.8%*		*17.0%*	*16.6%*	
EPS (Basic)	**5.56**	**4.39**	***26.7%***	**18.48**	**15.97**	***15.7%***
EPS (Diluted)	**5.55**	**4.39**	***26.4%***	**18.45**	**15.95**	***15.7%***

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.